Adaptimmune Therapeutics Plc ADR (ADAPY)

$HIMS $LULU $ADAPY $AGMH top watch >>

$ADAPY just want to point out that nothing has changed in our thesis we spent the last year piecing together. If you expected news already and it didn't come, doesn't mean it's not coming

$ADAPY green what we finished green !! lol stay positive at least for today

$ADAPY Guys, remember ChatPTB can and does lie. Also, anyone telling you there are about a million outstanding and unexercised options is lazy, not bright or both. Per the company, there are 139,590,747 ordinary shares remaining for directors and former employees (divide by 6 for ADS). And they awarded almost 50 million shares to themselves in 2025 alone! The truth is out there for those who seek it. USBull.

$ADAPY we will be in a cold. Period until something is announced. Nothing will make this stock rise till that happens. None of us. Know what is really going on yet. If you believe in it hold if not, then sell.

$ADAPY Based on the information I’ve provided, this is the ONLY possible path to creating generational wealth here. We need to do this. We need to stand a little closer to what we are leaning on.

$ADAPY additional context from sources believed to be reliable. The actual deal terms from the Asset Purchase Agreement between Adaptimmune ($ADAP/$ADAPY) and US WorldMeds structure the $30 million in contingent milestones across four specific triggers: | Milestone Event | Payout | Status / Likelihood | | BLA Acceptance: FDA acceptance of all modules for lete-cel | $5.0M | Pending BLA submission/acceptance. | | FDA Approval: Full marketing approval for lete-cel in SS/MRCLS | $10.0M | Pushed to late 2027/2028; at risk if time-bound windows expire. | | Tecelra Quarterly Revenue: Net US revenue \ge \$18\text{M} in any single quarter | $5.0M (2 \times 2.5\text{M}) | Unlikely in the near term given slow commercial uptake. | | Combined Revenue: Net US revenue for Tecelra + lete-cel \ge \$200\text{M} | $10.0M | Effectively off the table without volume scale and multiple indications. | What This Means for Realized Payouts and Valuation Zero Realized Milestones to Date: Beyond the initial $55 million upfront (over half of which immediately went to retire the Hercules Capital debt facility), Adaptimmune has probably realized $0 of the headline $30 million contingent consideration. The "Time-Bound" Trap: If the agreement enforces strict sunset dates for regulatory filings and approvals, slipping past 2026/2027 means the $15 million in regulatory milestones risks permanent forfeiture rather than mere deferral. Commercialization Velocity Disconnect: With single-digit patient volumes at top-tier centers like MSK, quarterly product revenues will not approach the $18 million/quarter run-rate required to trigger even the first $2.5 million commercial tranche. Valuation Impact: Modeling Adaptimmune as a recipient of high-margin milestone cash flows relies on projections detached from real-world cell therapy adoption curves. [US_Bull says they won’t believe this but if you say so] Stripped of these milestones, the remaining entity is the holder or a dormant pipeline (CD70) that’s become a treasury money market fund. Sorry. There’s nothing here? US_Bull